Skip to content
DataLookout
Menu

NCT05251493

Ferric Derisomaltose (Iron Isomaltoside) Versus Iron Sucrose for Treatment of Iron Deficiency in Pregnancy

StatusTerminated
PhasePhase 3
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 5 versions: 5 with changes below. See every version on ClinicalTrials.gov ↗

  1. Stopped Trial terminated Sponsor's reason: The monograph for the investigational drug (derisomaltose) was updated to include pregnancy as an indication for infusion. Enrollment significantly decreased and the study was stopped. Show 8 more changesShow less
    • Eligibility criteria expanded, about 27 words
    • Final enrollment: 113 participants (planned 280)
    • Primary completion date changed from estimate of Dec 31, 2026 to May 31, 2026
    • Study completion date changed from estimate of Feb 28, 2027 to Jun 1, 2026
    • Secondary endpoints: details revised at 5 of 5 entries
    • Study description revised
    • Site details revised
    • Publications: details revised at 8 of 8 entries
  2. Notable Primary completion date: Dec 31, 2024 to Dec 31, 2026
    • Study completion date: Feb 28, 2025 to Feb 28, 2027
    v4
  3. Notable Primary completion date: May 31, 2023 to Dec 31, 2024
    • Study completion date: May 31, 2023 to Feb 28, 2025
    v3
  4. Notable Trial status: Not Yet Recruiting to Recruitingv2 Show 4 more changesShow less
    • Study sites: 0 to 1
    • Primary and study completion dates: May 2023 to May 31, 2023
    • Start date changed from estimate of May 2022 to Jun 6, 2022
    • Secondary endpoints revised (5)
  5. Study First Submitted
  • Stopped: terminated, suspended or withdrawn
  • Notable: the plan changed

Endpoints

Primary

Correction of anemia
Timeframe: 30 days post iron infusion

Secondary (5)

Participant's tolerance to IV iron infusion
Comparison of participant's pregnancy related symptoms- subjective measure
Convenience/barriers of IV iron appointment(s)- subjective measure
Changes in Participant's Mental Health and Physical Well-Being
Reported bonding with baby-subjective

Arms and interventions

Iron Isomaltoside/ferric derisomaltoseActive comparator

route: intravenous Dosage: 1000-1500 mg (100mg/mL), max dose 20mg/kg Frequency: max dose 1000 mg, if further doses required, must receive dosage divided Duration: one infusion or two infusions (dose dependent)

Iron SucroseActive comparator

Route: Intravenous Dosage: 100 mg/mL (maximum 300 mg per dose) Frequency: up to 3 doses per week or 1000 mg per week maximum Duration: until iron needs reached by simplified table

Drugs: Iron Isomaltoside 1000, ferric derisomaltose, Iron sucrose

Sites

1 site in 1 country

  • Regina General HospitalRegina, Saskatchewan, Canada